Objectives-To describe a large series of patients with vertebral osteomyelitis (VO), and to compare the clinical, biological, radiological, and prognostic features of pyogenic (PVO), tuberculous (TVO), and brucellar vertebral osteomyelitis (BVO). Methods-A retrospective multicentre study, which included 219 adult patients with VO with confirmed aetiology, who were diagnosed between 1983 and 1995 in two tertiary care centres. Of these patients, 105 (48%) had BVO, 72 (33%) PVO, and 42 (19%) TVO. Results-One hundred and forty eight (67.6%) patients were male and 71 (32.4%) female. The mean (SD) age was 50.4 (16.4) years (range 14-84) and the mean (SD) duration of symptoms before the diagnosis was 14 (16.8) weeks. In 127 patients (57.9%) the vertebral level involved was lumbar, in 70 (31.9%) thoracic, and in 16 (7.3%) cervical. One hundred and nineteen patients (54.4%) received only medical treatment and 100 (45.6%) required both medical and surgical treatment. The presence of diabetes mellitus, intravenous drug abuse, underlying chronic debilitating diseases or immunosuppression, previous infections, preceeding bacteraemia, recent vertebral surgery, leucocytosis, neutrophilia, and increased erythrocyte sedimentation rate (ESR) were significantly associated to PVO. A prolonged clinical course, thoracic segment involvement, absence of fever, presence of spinal deformity, neurological deficit, and paravertebral or epidural masses, were significantly more frequent in the group of TVO. The need for surgical treatment and the presence of severe functional sequelae were more frequent in the groups of PVO and TVO. Conclusion-There are significant clinical, biological, radiological, and prognostic diVerences between BVO, PVO, and TVO. These diVerences can point to the causal agent and orient the initial empirical medical treatment while awaiting a final microbiological diagnosis. (Ann Rheum Dis 1997;56:709-715) In 1975 Ross and Fleming rightly pointed out "neither common enough to be readily recognizable, nor rare enough to be a medical curiosity, vertebral osteomyelitis (VO) represents a diagnostic challenge to the physician". 1The clinical picture of VO is rather nonspecific. It commonly starts insidiously and follows an indolent course making early diagnosis diYcult.2-4 Consequently, patients often develop highly destructive lesions or neurological complications related to compression of the spinal cord or its roots.
Infective endocarditis (IE) remains a major clinical problem, with mortality rates of 20% to 40%. [1][2][3] During the active course of IE, neurological complications occur in 20% to 40% of patients 1,4,5 and have been linked to a poorer outcome. 1,2,5,6 In several of the related reports, however, neurological complication is a generic term referring to a broad spectrum of complications ranging from nonspecific manifestations, such as nonfocal encephalopathy, seizures, or headache, to stroke or severe cerebral hemorrhage. 4,7 This all-inclusive approach can lead to confusion when investigating the true effect of brain involvement on the outcome of IE or the relationships between brain injury and certain characteristics Background-The purpose of this study was to assess the incidence of neurological complications in patients with infective endocarditis, the risk factors for their development, their influence on the clinical outcome, and the impact of cardiac surgery. Antimicrobial treatment reduced (by 33% to 75%) the risk of neurological complications. In patients with hemorrhage, mortality was higher when surgery was performed within 4 weeks of the hemorrhagic event (75% versus 40% in later surgery). Conclusions-Moderate to severe ischemic stroke and brain hemorrhage were found to have a significant negative impact on the outcome of infective endocarditis. Early appropriate antimicrobial treatment is critical, and transitory discontinuation of anticoagulant therapy should be considered. Methods and Results-This García-Cabrera et al Endocarditis, Neurological Complications 2273of IE (eg, vegetation size or affected valve). Another debated point requiring clarification is whether brain damage may worsen after valve surgery in patients experiencing these complications. Several of the previous studies investigating these and other issues have the limitations of retrospective data collection, 8,9 referral center bias, 8,10 or analysis of too few events to obtain valid conclusions. 4,8 Clinical Perspective on p 2284The objectives of the present study were to assess the incidence of neurological complications in IE patients, the risk factors for their development, the associated risk of death, and the influence of valve surgery in this situation on patient outcome. Methods Study Design and PatientsThe study included patients consecutively diagnosed with IE in 7 hospitals in Andalusia (southern Spain) and registered in a dedicated database from January 1984 to December 2009. Five of the participating centers are tertiary referral hospitals for cardiac surgery, and 2 are community hospitals, where patients at higher risk are transferred to the referral centers for assessment for surgery. The information in this database was merged with data from the Vall d'Hebron Hospital database for IE. Vall d'Hebron is a 1000-bed teaching hospital in Barcelona, Spain, and a referral center for cardiac surgery, with a prospective IE cohort registered from January 2000 to December 2009. The specific variables included in both registri...
We studied 31 cases of postoperative pyogenic spondylodiskitis (POS), comparing them with 72 cases of nonpostoperative pyogenic spondylodiskitis (NPOS). POS represents 30.1% of cases of pyogenic spondylodiskitis. The onset of symptoms occurred an average (+/-SD) of 27.7 (+/- 25.3) days following surgery. Predisposing factors were less frequent in POS than NPOS cases (P = .002). Neurological complications and inflammatory signs in the spine were more frequent with POS than with NPOS (P = .002 and P < .00001). Coagulase-negative Staphylococcus and anaerobic bacteria were more frequent in POS than in NPOS (P = .0001 and P = .05). Percutaneous bone biopsies yielded the etiology in 66.7% of cases, open bone biopsies in 100%, blood cultures in 55.6%, and cultures of adjacent foci in 94.4%. Eleven patients (35.5%) were cured with antimicrobial treatment, but surgical treatment was necessary in 64.5%. No relapses or deaths were recorded. Seventeen patients (54.8%) had severe functional sequelae, which were associated with inflammatory signs in the spine (P = .033), higher levels of leukocytosis (P = .05), higher erythrocyte sedimentation rates (P = .05), and paravertebral abscesses (P = .04).
Brucella endocarditis is an uncommon focal complication of brucellosis. Presented here are 11 cases of Brucella endocarditis, all managed uniformly. The median duration of symptoms prior to diagnosis was 3 months. Five patients (45%) had underlying valvular damage, and in six (55%) endocarditis involved a normal valve. There was a predominance of aortic involvement (82%) and a high incidence of left ventricular failure (91%). Diagnostic suspicion was essential in order to test blood cultures correctly, which in this series were positive in 63% of the patients. Surgical treatment was undertaken in eight patients (72%), all with aortic involvement and left ventricular failure impossible to control with medication. One patient died during the immediate postoperative period. All the other patients received antibiotic therapy for 3 months, with no signs of relapse of the infection or malfunction of the prosthesis during a minimum follow-up period of 24 months.
Vertebral osteomyelitis is a serious complication of brucellosis. It generates a high rate of therapeutic failure and functional sequelae. In the absence of more-powerful controlled studies, the duration of treatment of brucellar vertebral osteomyelitis should be 3 months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.